Kala Pharmaceuticals, Inc. announced that it has acquired Combangio, Inc. In conjunction with the acquisition, Mark S. Blumenkranz, M.D., Chairman of Combangio, has been appointed to the Kala Board of Directors, and Darius Kharabi, President and Chief Executive Officer of Combangio, has been appointed as Chief Business Officer of Kala, both effective November 15, 2021.